
What are the most pressing medical challenges when it comes to developing new drugs against antimicrobial resistance (AMR)?
The question was posed by a number of researchers, led by MD Lars Jørgen Østergaard, some years ago. With the aim of securing funds to develop new drugs, Østergaard contacted serial entrepreneur and investor Claus Hansen, ”who knows about the money side of things.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app